Methods and compositions for treating infectious conjunctivitis

A PVP-I composition with PVP and glycerin enhances ocular tolerability and efficacy against conjunctivitis, addressing the tolerability issues of PVP-I and avoiding anti-inflammatory drugs.

JP2024544247AInactive Publication Date: 2024-11-28HARROW IP LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534519
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-14
Filing Date
2022-12-13
Publication Date
2024-11-28
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Povidone-iodine (PVP-I) is effective against bacteria but has poor ocular tolerability and conflicting efficacy in treating viral conjunctivitis, and existing formulations often include steroidal or non-steroidal anti-inflammatory drugs to improve tolerability, which are undesirable.

Method used

A composition comprising PVP-I with excipients like polyvinylpyrrolidone (PVP) and glycerin improves ocular tolerability without using anti-inflammatory drugs, maintaining efficacy against infectious conjunctivitis.

Benefits of technology

The composition achieves comparable ocular tolerability to placebo controls and effectively reduces viral replication and shedding in conjunctivitis, without the adverse effects of anti-inflammatory drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544247000001_ABST
    Figure 2024544247000001_ABST
Patent Text Reader

Abstract

The present invention generally relates to a method of treating infectious conjunctivitis by administering to an infected eye of a subject a composition comprising povidone-iodine and an excipient that reduces the ocular toxicity of the composition, wherein the composition does not comprise a steroidal or non-steroidal anti-inflammatory drug.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Non-provisional Application No. 17 / 550,802, entitled “METHOD AND COMPOSITION FOR TREATING INFECTIOUS CONJUNCTIVITIS,” filed December 14, 2021, the entire contents of which are incorporated herein by reference.

[0002] The present invention relates to methods and compositions for treating infectious conjunctivitis. Thus, the present invention relates to the fields of pharmacology, medicine, and chemistry. [Background technology]

[0003] Povidone-iodine (PVP-I) is known for its antibacterial properties (Saggers, B. and Stewart, G., 1964). It is commonly available in most pharmacies and is widely used as a disinfectant. There is also no evidence of resistance to PVP-I, making it a particularly important tool in infection control. However, PVP-I has been avoided in ophthalmic formulations due to poor ocular tolerability observed at high concentrations. Furthermore, there are conflicting reports in the literature regarding the efficacy of PVP-I in treating viral conjunctivitis. Some solutions to this problem include using PVP-I in formulations containing steroidal and nonsteroidal anti-inflammatory drugs to improve ocular tolerability. What is needed is a method of treating infectious conjunctivitis by administering a solution containing PVP-I to the infected eye of a subject that does not exhibit high ocular toxicity or does not use steroidal or nonsteroidal anti-inflammatory drugs. Summary of the Invention

[0004] Among the various aspects of the present invention is a composition useful for treating infectious conjunctivitis. The composition includes PVP-I as an active ingredient, and is preferably effective in treating infectious conjunctivitis, and has no significant difference in ocular tolerability when compared to a placebo control. The composition further includes an excipient selected from polyvinylpyrrolidone (PVP), glycerin, or a combination thereof. The excipient may reduce the ocular tolerability of the composition to a level statistically similar to that of a placebo control on day 9 of the Draize rabbit eye test. Additionally, the composition does not include a steroidal or nonsteroidal anti-inflammatory drug. The ocular tolerability of the composition may be comparable to that of a placebo control without the use of a steroidal or nonsteroidal anti-inflammatory drug.

[0005] Another aspect of the present invention is a method for treating infectious conjunctivitis using the composition described herein. The method comprises administering a composition comprising a therapeutically effective amount of a composition that may comprise PVP-I as an active ingredient to the infected eye of a subject. The composition may also comprise an excipient that may reduce the ocular tolerability of the composition to a level statistically similar to that of a placebo control on day 9 of the Draize rabbit eye test. The method may not include the use of steroidal or nonsteroidal anti-inflammatory drugs. [Brief description of the drawings]

[0006] [Figure 1] 1 shows the results of a Draize ocular toxicity study conducted in rabbits, where Formulations 1A-1C contained biguazine polymer, Formulation 1D contained a composition of the present disclosure, and Formulation 1E contained a vehicle control. [Diagram 2] 1 shows the results of an Ad5 viral titer test measuring viral replication, where Formulations 1A-1C contained biguazine polymer, Formulation 1D contained a composition of the present disclosure, and Formulation 1E contained a vehicle control. [Diagram 3] The results of Ad5 positive cultures per total culture measuring viral replication are shown in Figure 1. Formulations 1A-1C contained biguazine polymer, formulation 1D contained a composition of the present disclosure, and formulation 1E contained a vehicle control. [Figure 4]1 shows the results of an Ad5 shedding duration study to determine the length of infection of Ad5. Formulations 1A-1C contained a biguazine polymer, formulation 1D contained a composition of the present disclosure, and formulation 1E contained a vehicle control. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] Before the present invention is disclosed and described, it is to be understood that the invention is not limited to the particular methods, compositions, or materials disclosed herein but extends to equivalents thereof as would be recognized by one of ordinary skill in the relevant art. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only and is not intended to be limiting.

[0008] In this specification, concentrations, amounts, and other numerical data may be expressed or presented in a range format. It should also be understood that such range formats are used merely for convenience and brevity, and should be interpreted flexibly to include not only the numerical values ​​explicitly recited as the limits of the range, but also all individual numerical values ​​or subranges subsumed within the range, as if each numerical value and subrange were explicitly recited. As an example, the numerical range "about 2 to about 50" should be interpreted to include not only the values ​​2 to 50 explicitly recited, but also all individual values ​​and subranges within the indicated range. Thus, included in this numerical range are: 2, 2.4, 3, 3.7, 4, 5.5, 10, 10.1, 14, 15, 15.98, 20, 20.13, 23, 25.06, 30, 35.1, 38.0, 40, 44, 44.6, 45, 48, and subranges such as 1-3, 2-4, 5-10, 5-20, 5-25, 5-30, 5-35, 5-40, 5-50, 2-10, 2-20, 2-30, 2-40, 2-50, etc. This same principle also applies to ranges which state only one numerical value as a minimum or maximum value. Moreover, such an interpretation should be applied regardless of the breadth of the range or the characteristics being described.

[0009] As used herein, the term "about" is used to provide flexibility to the endpoints of a numerical range by providing the possibility that a given value may be "a little above" or "a little below" the endpoint. For example, the endpoints may be within 10%, 8%, 5%, 3%, 2%, or 1% of the stated value. Furthermore, for convenience and brevity, a numerical range of "about 50 mg / mL to about 80 mg / mL" is understood to also support the range "50 mg / mL to 80 mg / mL". The endpoints may be based on the variability allowed by appropriate regulatory agencies, such as the FDA, USP, etc.

[0010] In this disclosure, "comprises," "comprising," "containing," "having," and the like, can have the meanings given them in U.S. Patent Law, and can mean "includes," "including," and the like, and are generally construed to be open-ended terms. The terms "consisting of" or "consists of" are closed-ended terms, including only those components, structures, steps, and the like specifically recited with such term, as well as in accordance with U.S. Patent Law. "consisting essentially of" or "consists essentially of" have the meanings generally given them in U.S. Patent Law. In particular, such terms are generally closed-ended terms, except that they permit the inclusion of additional items, materials, ingredients, steps, or elements that do not materially affect the basic and novel characteristics or function of the item(s) in connection therewith. For example, trace elements that are present in a composition but do not affect the properties or characteristics of the composition would be permitted if present under the phrase "consisting essentially of" even if they are not explicitly recited in a list of items following such a term. When open-ended terms such as "comprising" or "including" are used herein, it is understood that direct support should be given to the phrase "consisting essentially of" as well as the phrase "consisting of," and vice versa, as if expressly set forth.

[0011] As used herein, "subject" refers to a mammal. Examples of subjects include humans, and may also include other animals, such as horses, pigs, cows, dogs, cats, rabbits, and aquatic mammals. In one aspect, the subject may be a human.

[0012] As used herein, "ocular tolerance" and "ocular toxicity" refer to the degree to which overt adverse effects on a subject's eye can be tolerated by the subject or produce measurable toxicity, respectively. Ocular tolerance and ocular toxicity are inversely related. Ocular tolerance or ocular toxicity can be measured in humans or other suitable subjects. For example, ocular tolerance can be measured using the Draize scale. The Draize scale method involves instilling 100 μL of the test liquid into the inferior conjunctival sac and cornea of ​​one eye of a non-human subject (usually a rabbit), followed by rinsing with saline. The other eye of the subject does not receive the liquid and serves as a control eye to be compared with the treated eye. Corneal opacity, conjunctival hyperemia, chemosis, eye discharge, iris abnormalities, and other criteria are recorded at predefined intervals. The recorded symptoms are expanded into a "maximum mean score." The results of the Draize test can be used to describe the test solutions as non-irritating, practically non-irritating, minimally irritating, mildly irritating, moderately irritating, severely irritating, extremely irritating, or maximally irritating. The Draize test is the most commonly performed test to measure ocular tolerability.

[0013] Other methods to measure ocular tolerability include in vivo tests such as the small volume ocular irritation test (LVET). Unlike the Draize test, the LVET involves the injection of a small volume of the test substance (10 μL). However, animals are still used in the LVET. Furthermore, if no irritation occurs at the small volume in the LVET test, the standard procedure is to repeat the test with an increased volume. Ex vivo tests for ocular toxicity include isolated / enucleated organ / organotypic methods, but such tests cannot predict the systemic effects of a substance and can only be used for short evaluation periods. There are also in vitro tests to measure ocular toxicity, such as cytotoxicity assessments, corneal epithelial models, and corneal equivalents.

[0014] Another method for measuring ocular tolerability is the Comparison of Ophthalmic Medication for Ocular Tolerability (COMTOL). COMTOL is a questionnaire that patients fill out after administration of an ophthalmic drug. Further methods for measuring ocular tolerability are well known in the art.

[0015] On the other hand, ocular toxicity can be measured in several ways depending on the type of toxicity expected. For example, ocular toxicity can be measured by staining the corneal surface to measure epithelial damage or by measuring conjunctival hyperemia. Further methods for measuring ocular toxicity are well known in the art.

[0016] The terms "treat", "treating" or "treatment" as used herein refer to both therapeutic treatment and prophylactic or preventative measures, the purpose of which is to prevent or slow (alleviate) undesirable physiological changes or diseases / disorders. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, whether detectable or undetectable, reduction in the extent of disease, stable (i.e., not worsening) state of disease, delay or slowing of disease progression, improvement or palliation of disease symptoms, and remission (partial or complete). "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the disease, condition or disorder, as well as those prone to have the disease, condition or disorder or those in whom the disease, condition or disorder is to be prevented.

[0017] I. Compositions for Treating Infectious Conjunctivitis Described herein is a composition for treating infectious conjunctivitis, comprising povidone-iodine (PVP-I, also known as iodopovidone) and an excipient selected from polyvinylpyrrolidone (PVP), glycerin, or a combination thereof. The composition may also include one or more additional excipients, including but not limited to a pharma- ceutically acceptable carrier, a preservative, a pH adjuster, a surfactant, a stabilizer, or any combination thereof. In some embodiments, the composition is an aqueous solution. The compositions of the present disclosure are typically effective ophthalmic formulations for treating infectious conjunctivitis in subjects in need thereof, and preferably have a statistically similar level of ocular toxicity compared to a placebo control. As used herein, a "placebo control" is a composition that is structurally identical to the composition against which it is evaluated, except that the placebo control lacks PVP-I.

[0018] In some embodiments, the composition comprises a PVP-I concentration of about 0.6% (w / w) to about 1.25%. For example, the composition may comprise a PVP-I concentration of about 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1%, 1.05%, 1.1%, 1.15%, 1.2%, or 1.25% (w / w). In some examples, the concentration of PVP-I may be about 0.6% to about 1%, about 0.6% to about 0.9%, or about 0.6% to about 0.8% (w / w). In some examples, the concentration of PVP-I may be about 0.7% to about 1%, or about 0.7% to about 0.9% (w / w). In some examples, the concentration of PVP-I may be about 0.8% to about 1.2%, about 0.8% to about 1.1%, or about 0.8% to about 1.0% (w / w). In some examples, the concentration of PVP-I may be about 0.6% to about 0.7%, about 0.7% to about 0.8%, about 0.8% to about 0.9%, about 0.9% to about 1%, about 1% to about 1.1%, about 1.1% to about 1.2%, or about 1.2% to about 1.25% (w / w). In an exemplary embodiment, the concentration of PVP-I is about 0.8% (w / w). In certain embodiments, the composition may include PVP-I as the only active ingredient.

[0019] In some embodiments, the composition may include an amount of PVP, glycerin, or a combination thereof that improves ocular tolerability to the PVP-I in the composition. In some embodiments, the concentration of each excipient in the composition may be about 1.0% to about 2.5% (w / w). For example, the concentration of each excipient may be about 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, or about 2.5% (w / w). In other examples, the concentration of each excipient may be about 1.0% to about 1.1%, about 1.1% to about 1.2%, about 1.2% to about 1.3%, about 1.3% to about 1.4%, about 1.4% to about 1.5%, about 1.5% to about 1.6%, about 1.6% to about 1.7%, about 1.7% to about 1.8%, about 1.8% to about 1.9%, about 1.9% to about 2.0%, about 2.0% to about 2.1%, about 2.1% to about 2.2%, about 2.2% to about 2.3%, about 2.3% to about 2.4%, or about 2.4% to about 2.5% (w / w). Ocular tolerability can be measured by any suitable method known in the art. For example, ocular tolerability can be measured in human subjects during clinical trials. Alternatively, ocular tolerability can be measured in a suitable animal model, such as the Draize rabbit eye test detailed in the Examples. The amount of excipient(s) in the composition of the present disclosure can be shown to improve ocular tolerability by comparing it to an otherwise structurally identical composition lacking the excipient(s). Improved ocular tolerability can be a reduction in ocular toxicity after administration for two or more consecutive days (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more days), the reduction being about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or more. Alternatively, or in addition, the amount of excipient(s) in the compositions of the present disclosure may be shown to improve ocular tolerability if a composition including the excipient(s) reduces ocular toxicity to a level statistically similar to a placebo control.In exemplary embodiments, the improved ocular tolerability is measured after administration for at least 2 consecutive days (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or more days), more preferably after at least 7 consecutive days or after 9 consecutive days, and even more preferably after at least 14 consecutive days.

[0020] In some embodiments, the excipient can be PVP. The PVP can have a molecular weight of about 25,000 to about 40,000. In some aspects, the PVP can have a molecular weight of about 25,000 to about 30,000, about 30,000 to about 35,000, or about 35,000 to about 40,000. In some additional aspects, the PVP can have a molecular weight of about 25,000, 30,000, 35,000, or about 40,000. In some examples, the PVP can have a molecular weight of about 30,000.

[0021] The concentration of PVP in the composition may be about 0.5% to about 2.5%, or more preferably about 1.0% to about 2.5% (w / w). For example, the concentration of PVP may be about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, or 2.5% (w / w). In some examples, the concentration of PVP may be about 1.0% to about 2.2%, about 1.0% to about 2.0%, about 1.0% to about 1.8%, or about 1.0% to about 1.5%. In some examples, the concentration of PVP can be from about 0.7% to about 1.3%, from about 0.8% to about 1.2%, or from about 0.9% to about 1.1%. In some examples, the concentration of PVP can be about 0.9% to about 1.0%, about 1.0% to about 1.1%, about 1.1% to about 1.2%, about 1.2% to about 1.3%, about 1.3% to about 1.4%, about 1.4% to about 1.5%, about 1.5% to about 1.6%, about 1.6% to about 1.7%, about 1.7% to about 1.8%, about 1.8% to about 1.9%, about 1.9% to about 2.0%, about 2.0% to about 2.1%, about 2.1% to about 2.2%, about 2.2% to about 2.3%, about 2.3% to about 2.4%, or about 2.4% to about 2.5% (w / w). In some examples, the concentration of PVP is about 1%. In some examples, the PVP is PVP-k30.

[0022] In some embodiments, the excipient may be glycerin. The concentration of glycerin in the composition may be about 1.0% to about 2.5% (w / w). For example, the concentration of glycerin may be about 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, or 2.5% (w / w). In some examples, the concentration of PVP may be about 1.0% to about 2.2%, about 1.0% to about 2.0%, about 1.0% to about 1.8%, or about 1.0% to about 1.5%. In some examples, the concentration of PVP can be from about 1.3% to about 2.5%, from about 1.5% to about 2.5%, from about 1.7% to about 2.5%, or from about 2.0% to about 2.5%. In other examples, the concentration of glycerin can be about 1.0% to about 1.1%, about 1.1% to about 1.2%, about 1.2% to about 1.3%, about 1.3% to about 1.4%, about 1.4% to about 1.5%, about 1.5% to about 1.6%, about 1.6% to about 1.7%, about 1.7% to about 1.8%, about 1.8% to about 1.9%, about 1.9% to about 2.0%, about 2.0% to about 2.1%, about 2.1% to about 2.2%, about 2.2% to about 2.3%, about 2.3% to about 2.4%, or about 2.4% to about 2.5% (w / w). In some embodiments, the concentration of glycerin is about 1.25% (w / w).

[0023] In some embodiments, the excipients can be glycerin and PVP. The concentration of glycerin can be about 1.0% and about 2.5% (w / w), and the concentration of PVP in the composition can be about 0.5% and about 2.5% (w / w). In various examples, the concentrations of glycerin and PVP can be as described in the previous paragraph. In some embodiments, the concentration of PVP is about 0.8% to about 1.2% (w / w), and the concentration of glycerin is about 1.0% to about 1.5% (w / w). In some embodiments, the concentration of PVP is about 1% to about 1.5% (w / w), and the concentration of glycerin is about 1.0% to about 1.5% (w / w). In some embodiments, the concentration of PVP is about 1% (w / w), and the concentration of glycerin is about 1.25% (w / w).

[0024] The compositions described herein do not include an amount of steroidal anti-inflammatory drug(s) or non-steroidal anti-inflammatory drug(s) that improves the ocular tolerability of the composition. Examples of steroidal anti-inflammatory drugs include betamethasone, corticosteroids, dexamethasone, fluromethalone, hydrocortisone acetate, prednisolone, rimexolone, loteprednol etabonate, and other steroidal anti-inflammatory drugs known in the art. Examples of non-steroidal anti-inflammatory drugs include bromfenac, diclofenac, flurbiprofen sodium, ketorolac tromethamine, nepafenac, and other non-steroidal anti-inflammatory drugs known in the art. The compositions described herein also do not include an amount of N-acetylcysteine ​​that improves the ocular tolerability of the composition. Thus, in certain embodiments, the composition of the present disclosure may consist essentially of (a) PVP-I, (b) an excipient selected from PVP, glycerin, or a combination thereof, and (c) one or more additional active ingredients or excipients, with the proviso that the component (c) does not significantly affect the ocular tolerability of the composition. In yet other embodiments, the composition of the present disclosure may consist essentially of (a) PVP-I, (b) an excipient selected from PVP, glycerin, or a combination thereof, and (c) one or more additional excipients, each independently selected from the group consisting of a pH adjuster, a preservative, a stabilizer, and a surfactant, with the proviso that the component (c) does not significantly affect the ocular tolerability of the composition. The method of determining whether a drug or excipient improves the ocular tolerability of a composition is as described above. In an exemplary embodiment, the ocular tolerability is evaluated on day 9 of the Draize rabbit eye test.

[0025] In some embodiments, the composition may include a demulcent. In some aspects, the demulcent may be polyethylene glycol, polysorbates (e.g., polysorbate 80), polyvinyl alcohol, propylene glycol, glycerin, cellulose derivatives (e.g., sodium carboxymethylcellulose, hydroxyethylcellulose, hypromellose, and methylcellulose), dextran 70, gelatin, and other demulcents known in the art, and combinations thereof. When the demulcent is polyethylene glycol, the molecular weight of the polyethylene glycol may be about 300 (PEG-300) to about 400 (PEG-400).

[0026] The emollient may have a concentration in the composition of about 0.1% (w / w) to about 5% (w / w). In some embodiments, the emollient may have a concentration in the composition of about 0.1% (w / w) to about 0.5% (w / w), about 0.5% (w / w) to about 1% (w / w), about 1% (w / w) to about 1.5% (w / w), about 1.5% (w / w) to about 2% (w / w), about 2% (w / w) to about 2.5% (w / w), about 2.5% (w / w) to about 3% (w / w), about 3% (w / w) to about 3.5% (w / w), about 3.5% (w / w) to about 4% (w / w), about 4% (w / w) to about 4.5% (w / w), or about 4.5% (w / w) to about 5% (w / w). In some additional embodiments, the emollient is present in the composition at about 0.1% (w / w) to about 4.5% (w / w), about 0.1% (w / w) to about 4% (w / w), about 0.1% (w / w) to about 3.5% (w / w), about 0.1% (w / w) to about 3% (w / w), about 0.1% (w / w) to about 2.5% (w / w), about 0.1% (w / w) to about 2% (w / w), about 0.1% (w / w) to about 1.5% (w / w), , about 0.1% (w / w) to about 1% (w / w), about 0.5% (w / w) to about 5% (w / w), about 1% (w / w) to about 5% (w / w), about 1.5% (w / w) to about 5% (w / w), about 2% (w / w) to about 5% (w / w), about 2.5% (w / w) to about 5% (w / w), about 3% (w / w) to about 5% (w / w), about 3.5% (w / w) to about 5% (w / w), or about 4% (w / w). In yet another embodiment, the emollient may have a concentration of about 0.1% (w / w), 0.2% (w / w), 0.3% (w / w), 0.4% (w / w), 0.5% (w / w), 0.6% (w / w), 0.7% (w / w), 0.8% (w / w), 0.9% (w / w), 1% (w / w), 1.5% (w / w), 2% (w / w), 2.5% (w / w), 3% (w / w), 3.5% (w / w), 4% (w / w), 4.5% (w / w), or about 5% (w / w). In one example, the emollient is PEG-400, and the PEG-400 has a concentration of about 4% (w / w) in the composition.

[0027] To maintain the stability of the composition, the pH of the composition must be controlled. The pH of the composition may be about 4.2 to about 4.5. In some examples, the pH of the composition may be about 4.2, 4.3, 4.4, or 4.5. In some embodiments, the composition may include a pH adjuster (e.g., an acid, a base, a buffer) to achieve or maintain a desired pH. The pH adjuster may include dibasic sodium phosphate, boric acid, citric acid, or a combination thereof.

[0028] In some embodiments, the pH adjuster may include citric acid. In some aspects, the citric acid may have a concentration of about 0.1% (w / w) to about 1% (w / w) in the composition. In some additional aspects, the concentration of citric acid may be about 0.1% (w / w) to about 0.7% (w / w), about 0.1% (w / w) to about 0.5% (w / w), or about 0.1% (w / w) to about 0.3% (w / w). In further additional embodiments, citric acid may have a concentration in the composition of from about 0.1% (w / w) to about 0.2% (w / w), from about 0.2% (w / w) to about 0.3% (w / w), from about 0.3% (w / w) to about 0.4% (w / w), from about 0.4% (w / w) to about 0.5% (w / w), from about 0.5% (w / w) to about 0.6% (w / w), from about 0.6% (w / w) to about 0.7% (w / w), from about 0.7% (w / w) to about 0.8% (w / w), from about 0.8% (w / w) to about 0.9% (w / w), or from about 0.9% (w / w) to about 1% (w / w). In yet another embodiment, citric acid may have a concentration of about 0.1% (w / w), 0.2% (w / w), 0.3% (w / w), 0.4% (w / w), 0.5% (w / w), 0.6% (w / w), 0.7% (w / w), 0.8% (w / w), 0.9% (w / w), or about 1% (w / w) in the composition. In one example, citric acid has a concentration of about 0.2% (w / w) in the composition.

[0029] In some embodiments, the pH adjuster may include dibasic sodium phosphate. In some aspects, the dibasic sodium phosphate may have a concentration in the composition of about 0.3% (w / w) to about 1.5% (w / w). In some additional aspects, the dibasic sodium phosphate may have a concentration in the composition of about 0.3% (w / w) to about 1% (w / w), or about 0.3% to about 0.5% (w / w). In still further additional aspects, the dibasic sodium phosphate may have a concentration in the composition of about 0.3% (w / w) to about 0.4% (w / w), about 0.4% (w / w) to about 0.5% (w / w), about 0.5% (w / w) to about 0.6% (w / w), about 0.6% (w / w) to about 0.7% (w / w), about 0.7% (w / w) to about 0.8% (w / w), about 0.8% (w / w), or about 0.8% (w / w). ) to about 0.9% (w / w), about 0.9% (w / w) to about 1% (w / w), about 1% (w / w) to about 1.1% (w / w), about 1.1% (w / w) to about 1.2% (w / w), about 1.2% (w / w) to about 1.3% (w / w), about 1.3% (w / w) to about 1.4% (w / w), or about 1.4% (w / w) to about 1.5% (w / w). In yet another embodiment, the dibasic sodium phosphate may have a concentration of about 0.3% (w / w), 0.4% (w / w), 0.5% (w / w), 0.6% (w / w), 0.7% (w / w), 0.8% (w / w), 0.9% (w / w), 1% (w / w), 1.1% (w / w), 1.2% (w / w), 1.3% (w / w), 1.4% (w / w), or about 1.5% (w / w). In one example, the dibasic sodium phosphate has a concentration of about 0.3% (w / w) in the composition.

[0030] In some embodiments, the pH adjuster may be a combination of citric acid and dibasic sodium phosphate. In one example, the pH adjuster is a combination of citric acid and dibasic sodium phosphate, where the citric acid has a concentration of about 0.2% (w / w) in the composition and the dibasic sodium phosphate has a concentration of about 0.3% (w / w) in the composition.

[0031] In some embodiments, the composition includes one or more preservatives. The preservatives may include benzalkonium chloride, thimerosal, chlorobutanol, methylparaben, propylparaben, phenylethyl alcohol, EDTA, sorbic acid, polyquaternium 1, or combinations thereof. In some embodiments, the preservatives may have a concentration of about 0.001% to about 0.1% (w / w) in the composition. For example, the concentration of the preservatives may be about 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or about 0.1% (w / w). In other examples, the concentration of the preservative is about 0.001% to about 0.002%, about 0.002% to about 0.003%, about 0.003% to about 0.004%, about 0.004% to about 0.005%, about 0.006% to about 0.007%, about 0.007% to about 0.008%, about 0.008% to about 0.009%, about 0.009% to about 0.008%, about 0.009% to about 0.009 ... % to about 0.01%, about 0.01% to about 0.02%, about 0.02% to about 0.03%, about 0.03% to about 0.04%, about 0.05% to about 0.06%, about 0.06% to about 0.07%, about 0.07% to about 0.08%, about 0.08% to about 0.09%, or about 0.09% to about 0.1% (w / w).

[0032] In some embodiments, the preservative may be a combination of benzalkonium chloride and EDTA. The concentration of benzalkonium chloride and the concentration of EDTA in the composition may each be about 0.001% to about 0.1% (w / w). For example, the concentration of benzalkonium chloride may be about 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or about 0.1% (w / w). and the concentration of EDTA may be about 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or about 0.1% (w / w). In other examples, the concentration of benzalkonium chloride is about 0.001% to about 0.002%, about 0.002% to about 0.003%, about 0.003% to about 0.004%, about 0.004% to about 0.005%, about 0.006% to about 0.007%, about 0.007% to about 0.008%, about 0.008% to about 0.009% , about 0.009% to about 0.01%, about 0.01% to about 0.02%, about 0.02% to about 0.03%, about 0.03% to about 0.04%, about 0.05% to about 0.06%, about 0.06% to about 0.07%, about 0.07% to about 0.08%, about 0.08% to about 0.09%, or about 0.09% to about 0.1% (w / w ), and the concentration of EDTA may be about 0.001% to about 0.002%, about 0.002% to about 0.003%, about 0.003% to about 0.004%, about 0.004% to about 0.005%, about 0.006% to about 0.007%, about 0.007% to about 0.008%, about 0.008% to about 0.009%, about 0.00 It may be about 9% to about 0.01%, about 0.01% to about 0.02%, about 0.02% to about 0.03%, about 0.03% to about 0.04%, about 0.05% to about 0.06%, about 0.06% to about 0.07%, about 0.07% to about 0.08%, about 0.08% to about 0.09%, or about 0.09% to about 0.1% (w / w). For example, the composition may contain benzalkonium chloride at a concentration of about 0.003% (w / w) and EDTA at a concentration of about 0.1% (w / w).

[0033] The composition may include a surfactant. In general, non-ionic surfactants are preferred because they do not bind to PVP-I. In some embodiments, the surfactant may include polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polysorbate 20, polysorbate 60, polysorbate 80, poly(oxyethylene-co-oxypropylene) block copolymers, poloxamers, Pluronic® F-68, Pluronic® F-84, Pluronic® F-127, Pluronic® P-103, cyclodextrin, nonoxynol-9, nonylphenoxypoly(ethyleneoxy)ethanol, Igepal Co-630, tyloxapol, or combinations thereof. The concentration of the surfactant may be about 0.01% to 2% (w / w). For example, the concentration of the surfactant in the composition can be about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, or 2% (w / w). In another example, the concentration of the surfactant is about 0.01% to about 0.02%, about 0.02% to about 0.03%, about 0.03% to about 0.04%, about 0.04% to about 0.05%, about 0.05% to about 0.06%, about 0.06% to about 0.07%, about 0.07% to about 0.08%, about 0.08% to about 0.09%, about 0.09% to about 0.1%, about 0.1% to about 0.2%, about 0.2% to about 0.3%, about 0.3% to about 0.4%, about 0.4% to about 0.5%, about 0.5% to about 0.6%, about 0.6% to about 0.7%, about 0.7% to about 0.8%, about 0.8% to about 0.9%, about 0.9% to about 0.1%, about 0.1% to about 0.2%, about 0.2% to about 0.3%, about 0.3% to about 0.4%, about 0.4% to about 0.5%, about 0.5% to about 0.6%, about 0.5% to about 0.7%, about 0.5% to about 0.8%, about 0.5% to about 0.9 ... %, about 0.5% to about 0.6%, about 0.6% to about 0.7%, about 0.7% to about 0.8%, about 0.8% to about 0.9%, about 0.9% to about 1%, about 1% to about 1.1%, about 1.1% to about 1.2%, about 1.2% to about 1.3%, about 1.3% to about 1.4%, about 1.4% to about 1.5%, about 1.5% to about 1.6%, about 1.6% to about 1.7%, about 1.7% to about 1.8%, about 1.8% to about 1.9%, or about 1.9% to about 2% (w / w).In one example, the surfactant is tyloxapol and has a concentration of about 0.02% to about 0.5% (w / w). In another example, the surfactant is tyloxapol at a concentration of about 0.3% (w / w).

[0034] The composition may further comprise a stabilizer. In some embodiments, the stabilizer may comprise calcium chloride, magnesium chloride, sodium chloride or other chloride salts. The stabilizer may have a concentration of about 0.1% to about 0.9% in the composition. For example, the stabilizer may have a concentration of about 0.1% (w / w), 0.2% (w / w), 0.3% (w / w), 0.4% (w / w), 0.5% (w / w), 0.6% (w / w), 0.7% (w / w), 0.8% (w / w), or about 0.9% (w / w) in the composition. In one embodiment, the stabilizer is sodium chloride at a concentration of about 0.2% (w / w).

[0035] The composition may further comprise water. In some embodiments, the composition is an aqueous solution. In some embodiments, the composition may be a viscous solution. In some aspects, the composition may have a viscosity of about 1 cP to about 100 cP. In some additional aspects, the composition may have a viscosity of about 1 cP to about 5 cP, about 5 cP to about 10 cP, about 10 cP to about 20 cP, about 20 cP to about 30 cP, about 30 cP to about 40 cP, about 40 cP to about 50 cP, about 50 cP to about 60 cP, about 60 cP to about 70 cP, about 70 cP to about 80 cP, about 80 cP to about 90 cP, or about 90 cP to about 100 cP. In further embodiments, the composition may have a viscosity of about 1 cP to about 90 cP, about 1 cP to about 80 cP, about 1 cP to about 70 cP, about 1 cP to about 60 cP, about 1 cP to about 50 cP, about 1 cP to about 40 cP, about 1 cP to about 30 cP, about 1 cP to about 20 cP, about 1 cP to about 10 cP, about 5 cP to about 100 cP, about 10 cP to about 100 cP, about 20 cP to about 100 cP, about 30 cP to about 100 cP, about 40 cP to about 100 cP, about 50 cP to about 100 cP, about 60 cP to about 100 cP, about 70 cP to about 100 cP, or about 90 cP to about 100 cP. In yet another embodiment, the composition may have a viscosity of about 1 cP, 5 cP, 10 cP, 20 cP, 30 cP, 40 cP, 50 cP, 60 cP, 70 cP, 80 cP, 90 cP, or about 100 cP.

[0036] In an exemplary embodiment, the composition comprises about 0.6% (w / w) to about 1.25% (w / w) PVP-I, about 1% (w / w) to about 2% (w / w) glycerin, about 1% (w / w) to about 2% (w / w) PVP, about 0.1% (w / w) to about 1% (w / w) citric acid, about 0.3% (w / w) to about 1.5% (w / w) dibasic sodium phosphate, about 0.001% (w / w) to about 0.1% (w / w) benzalkonium chloride, about 0.1% (w / w) to about 0.9% (w / w) sodium chloride, about 4% (w / w) PEG-400, and an appropriate amount of water for injection, wherein the composition has a pH of about 4.2 to about 4.5. In another exemplary embodiment, the composition comprises about 0.8% (w / w) PVP-I, about 1.25% (w / w) glycerin, about 1% (w / w) PVP, about 0.2% (w / w) citric acid, about 0.3% (w / w) dibasic sodium phosphate, about 0.003% (w / w) benzalkonium chloride, about 0.2% (w / w) sodium chloride, about 4% (w / w) PEG-400, and water for injection, qs, wherein the composition has a pH of about 4.2 to about 4.5.

[0037] Preferably, the composition does not include cooling agents that may improve the ocular tolerability of the composition. Cooling agents that may not be included in the composition of the present disclosure include menthol; menthol derivatives including methone glycerol acetyl and menthyl esters, carboxamides, menthane glycerol ketals, alkyl-substituted ureas, sulfonamides, terpene analogs, furanones, and phosphine oxides; camphor, and borneol.

[0038] In one example, the composition is prepared by first providing water for injection, then sequentially adding and dissolving pH adjusters, stabilizers, excipients, emollients, PVP-I, and preservatives.The pH can then be measured and adjusted.Finally, water for injection is added to the desired final volume.

[0039] II. Methods of Treating Infectious Conjunctivitis Described herein are methods of treating infectious conjunctivitis in a subject in need thereof. The method comprises administering a therapeutically effective amount of a composition of section I to the infected eye of the subject. In some embodiments, the method comprises administering to the infected eye of the subject a therapeutically effective amount of a composition comprising about 0.6%-1.25% (w / w) povidone-iodine and an amount of an excipient selected from polyvinylpyrrolidone, glycerin, or a combination thereof, wherein the amount of excipient reduces the ocular toxicity of povidone-iodine to a level statistically similar to a placebo control. In some embodiments, the method comprises administering to the infected eye of the subject a therapeutically effective amount of a composition comprising about 0.6%-1.25% (w / w) povidone-iodine, about 1-2% (w / w) polyvinylpyrrolidone, and about 1-2% (w / w) glycerin, wherein the composition produces a statistically similar level of ocular toxicity compared to a placebo control. In some embodiments, the method may include administering the composition to a non-infected eye of a subject, for example, to prevent infection of the non-infected eye while the infected eye is being treated. Additional aspects of suitable compositions are described in Section I, which is incorporated herein by reference.

[0040] In some embodiments, the type of infectious conjunctivitis can be bacterial conjunctivitis. For example, the method can be used to treat bacterial conjunctivitis caused by Staphylococcus aureus, coagulase-negative Staphylococcus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa, Serratia marcescens, Streptococcus pneumoniae, Haemophilus influenzae, or other bacterial species.

[0041] In some embodiments, the type of infectious conjunctivitis can be viral conjunctivitis. For example, the method can be used to treat viral conjunctivitis caused by adenovirus, herpes simplex virus, enterovirus, or other viral species.

[0042] The methods described herein include administering a therapeutically effective amount of the composition of Section I. As used herein, the term "therapeutically effective amount" refers to an amount that provides a measurable beneficial effect, i.e., significant efficacy, to the subject to whom the substance is administered. In some embodiments, the methods of the present disclosure may result in a measurable improvement in the symptoms or clinical signs of infectious conjunctivitis. Non-limiting symptoms and clinical signs of infectious conjunctivitis include conjunctival hyperemia, discharge, eye irritation, eye inflammation, positive microbial or viral testing of eye samples (e.g., fluids, discharges, scrapes, etc.), and the like. The therapeutically effective amount administered can be determined using standard techniques in the art and may be influenced by the circumstances surrounding the case, e.g., type of conjunctivitis, severity of disease, and the like. The therapeutically effective amount can be administered over any suitable number of doses, e.g., as 1, 2, 3, 4 or more doses per day, where a "dose" is the specified number of drops per eye. In one example, the therapeutically effective amount is administered in multiple doses, such as 4 doses per eye per day. In another example, the therapeutically effective amount is administered in multiple doses, such as two doses per eye per day. In yet another example, one dose is considered to be one drop of the composition.

[0043] In some embodiments, the methods of the disclosure may result in a reduction in viral or microbial replication measured in an ocular fluid sample obtained from a subject after at least two days of treatment (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or more) compared to an ocular fluid sample obtained from the subject prior to administration of the composition, or compared to viral or microbial replication measured in an ocular fluid sample obtained from a subject administered a placebo control. Alternatively or additionally, in some embodiments, the method may result in a reduction in the viral or microbial titer measured in an ocular fluid sample obtained from a subject after at least two days of treatment (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or more) compared to a sample of the subject obtained before administration of the composition, or compared to a sample of the subject obtained from a placebo control. A higher viral or microbial replication rate or a higher viral or microbial titer generally indicates a more severe infection, and the amount of change in replication or titer is a direct measure of efficacy. In some examples, the reduction in viral or microbial titer may be a log 3 reduction in viral or microbial titer after at least two days of treatment (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or more). In some embodiments, the method may result in an increase in negative cultures from samples of ocular fluid obtained from a subject after at least two days of treatment (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or more) compared to samples obtained from the subject prior to administration of the composition or compared to samples obtained from subjects administered a placebo control. Generally, a higher proportion of positive cultures obtained over consecutive days indicates a more severe infection, and the change in the proportion of negative cultures over the same number of days is a direct measure of efficacy.

[0044] In some embodiments, the methods may result in a decrease in the duration of viral shedding from an ocular fluid sample obtained from a subject after at least 2 days (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days or more) of treatment compared to viral shedding measured in an ocular fluid sample obtained before administration of the composition or compared to viral shedding measured in an ocular fluid sample obtained from a subject administered a placebo control. Longer duration of viral shedding indicates severe infection and the amount of change in duration of viral shedding is a direct measure of efficacy.

[0045] III. How to prevent infection Described herein are methods of preventing infection in a subject. The method comprises administering to the non-infected eye of the subject an effective amount of the composition of section I. In some embodiments, the method comprises administering to the non-infected eye of the subject a therapeutically effective amount of a composition comprising about 0.6%-1.25% (w / w) povidone-iodine and an amount of an excipient selected from polyvinylpyrrolidone, glycerin, or a combination thereof, wherein the amount of excipient reduces the ocular toxicity of povidone-iodine to a level statistically similar to a placebo control. The method may be useful for prophylactically preventing infection in one or both eyes.

[0046] In some embodiments, the methods may be useful for preventing infection following ophthalmic surgery or procedures to prevent infection in one or both eyes. In some aspects, the ophthalmic surgery or procedures may include cataract surgery, MIGS procedures, LASIK, keratoplasty, or other ophthalmic surgery or procedures known in the art.

[0047] Exemplary embodiments Embodiment 1: A method for treating infectious conjunctivitis in a subject in need thereof, comprising administering to the infected eye of the subject a therapeutically effective amount of a composition comprising about 0.6-1.25% (w / w) povidone-iodine and an amount of an excipient selected from polyvinylpyrrolidone, glycerin, or a combination thereof, wherein the amount of excipient reduces the ocular toxicity of the composition to a level statistically similar to a placebo control on Day 9 of a Draize Rabbit Eye Study, and wherein the composition does not comprise a steroidal or non-steroidal anti-inflammatory drug.

[0048] Embodiment 2: The method of embodiment 1, wherein the povidone-iodine has a concentration of about 0.8% (w / w).

[0049] Embodiment 3: The method of embodiment 1 or embodiment 2, wherein the composition comprises polyvinylpyrrolidone.

[0050] Embodiment 4: The method of embodiment 3, wherein the composition comprises about 1-2% (w / w) polyvinylpyrrolidone.

[0051] Embodiment 5: The method of embodiment 4, wherein the composition further comprises a preservative, a surfactant, a pH adjuster, a stabilizer, a emollient, or any combination thereof.

[0052] Embodiment 6: The method of any one of embodiments 1 to 5, wherein the composition comprises glycerin.

[0053] Embodiment 7: The method of embodiment 6, wherein the composition comprises about 1-2% (w / w) glycerin.

[0054] Embodiment 8: The method of any one of embodiments 1 to 7, wherein the composition comprises glycerin and polyvinylpyrrolidone.

[0055] Embodiment 9: The method of any one of embodiments 1 to 8, wherein the composition comprises about 1-2% (w / w) polyvinylpyrrolidone and about 1-2% (w / w) glycerin.

[0056] Embodiment 10: The method of embodiment 5, wherein the composition comprises a preservative.

[0057] Embodiment 11: The method of embodiment 5 or embodiment 10, wherein the preservative is selected from the group consisting of benzalkonium chloride, thimerosal, chlorobutanol, methylparaben, propylparaben, phenylethyl alcohol, EDTA, sorbic acid, polyquaternium 1, and any combination thereof.

[0058] Embodiment 12: The method of any one of embodiments 5, 10, or 11, wherein the preservative has a concentration of about 0.001% to 1.0% by weight in the composition.

[0059] Embodiment 13: The method of embodiment 5, wherein the composition comprises a surfactant.

[0060] Embodiment 14: The method of embodiment 5 or embodiment 13, wherein the surfactant is selected from the group consisting of Polysorbate 20, Polysorbate 60, Polysorbate 80, Pluronic® F-68, Pluronic® F-84, Pluronic® F-127, Pluronic® P-103, cyclodextrin, nonoxynol-9, Igepal Co-630, tyloxapol, and any combination thereof.

[0061] Embodiment 15: The method of any one of embodiments 5, 13, or 14, wherein the surfactant has a concentration of about 0.01% to 2% by weight in the composition.

[0062] Embodiment 16: The method of embodiment 5, wherein the emollient comprises polyethylene glycol at a concentration of about 4% (w / w).

[0063] Embodiment 17: The method of any one of embodiments 1 to 16, wherein the composition has a pH of about 4.2 to 4.5.

[0064] Embodiment 18: The method of any one of embodiments 1 to 17, wherein the composition has a pH of about 4.3.

[0065] Embodiment 19: The method of any one of embodiments 1 to 18, wherein the composition is a viscous solution.

[0066] Embodiment 20: The method of any one of the preceding embodiments, wherein the composition does not comprise a steroidal anti-inflammatory drug, a non-steroidal anti-inflammatory drug, menthol, a menthol derivative, borneol, camphor, or N-acetylcysteine ​​in an amount that improves ocular tolerability of the composition.

[0067] Embodiment 21: The method of any one of embodiments 1 to 20, wherein the infectious conjunctivitis is bacterial conjunctivitis.

[0068] Embodiment 22. The method of any one of embodiments 1 to 20, wherein the infectious conjunctivitis is viral conjunctivitis.

[0069] Embodiment 23: The method of embodiment 22, wherein the viral conjunctivitis is caused by an adenovirus, a herpes simplex virus, or an enterovirus.

[0070] Embodiment 24: The method of embodiment 22, wherein the viral conjunctivitis is caused by an adenovirus.

[0071] Embodiment 25: The method of any one of embodiments 22 to 24, wherein the treatment results in a measured reduction in viral replication compared to a placebo control.

[0072] Embodiment 26: The method of any one of embodiments 22 to 24, wherein the treatment results in a decrease in viral titer compared to a placebo control.

[0073] Embodiment 27: The method of any one of embodiments 22 to 24, wherein the treatment results in a reduction in positive cultures compared to a placebo control.

[0074] Embodiment 28: The method of any one of embodiments 22 to 24, wherein the treatment results in a decrease in duration of viral shedding compared to a placebo control. EXAMPLES

[0075] The following examples illustrate various implementations of the present invention.

[0076] Example 1 - In vivo rabbit model study The disclosed compositions, which enhance the ocular tolerability and efficacy of PVP-I compositions, were tested in vivo in New Zealand White rabbit specimens against adenovirus type 5 (Ad5; Ad5 / NZW rabbit ocular model). The purpose of the study was to determine the antiviral efficacy of several concentrations and dosing regimens of the disclosed compositions in the Ad5 / NZW rabbit ocular model.

[0077] The composition of the present disclosure used in this study included 0.8% PVP-I, 0.003% benzalkonium chloride, 0.3% tyloxapol, 0.1% dibasic sodium phosphate, 0.1% boric acid, 0.1% calcium chloride, 0.1% EDTA, 1% PVP, 1.25% glycerin, and water. The comparative composition included the same formulation, but used a biguanidine polymer instead of PVP-I. The vehicle composition included the same formulation, but did not include PVP-I or biguanidine polymer.

[0078] In this study, rabbits were treated according to the regimen shown in Table 1. The povidone-iodine composition was compared to the biguanide polymer composition. Five rabbits were administered the vehicle containing no active ingredient eight times daily for 10 days. One rabbit in the vehicle control group was ordered euthanized on the seventh day due to poor health. [Table 1-1]

[0079] Outcome variables tracked in this study included ocular tolerability (utilizing the Draize scale), Ad5 viral titers (measuring viral replication), Ad5 positive cultures (measuring viral replication), and duration of Ad5 shedding (determining the duration of infection).

[0080] Ocular Tolerance. The results of the ocular tolerability study are shown in FIG. 1. The study showed that there was no significant difference in ocular tolerability between the groups, including the placebo control group, on days 3 and 9 (day 3 refers to the third day of treatment). On day 3, the PVP-I composition was described as "mildly irritating" according to the Draize test, and the placebo control was described as "minimally irritating." On day 9, both the PVP-I composition and the placebo control were described as "moderately irritating" according to the Draize test. This result indicates that the PVP-I composition did not show a significant difference in ocular toxicity compared to the placebo control group.

[0081] Ad5 viral titer. The results of the Ad5 viral titer study are shown in FIG. 2. The study showed a statistically significant decrease in viral titer on day 9 of the regimen (p-value=0.0001). On day 9, the median viral titer detected in the group receiving the PVP-I composition was zero. The median viral titer detected in the placebo control group dropped to zero on day 14. This result indicates that the PVP-I composition slowed viral replication more effectively than the placebo control.

[0082] Ad5 positive cultures per total. The results of Ad5 positive cultures per total test are shown in FIG. 3. In all groups in the test, except the placebo control group, the consecutive decrease in positive cultures began on day 4. In rabbits administered 0.8% PVP-I, the decrease in positive cultures by day 9 was statistically significant (p-value=0.0004). By day 11, there were zero positive cultures for the group administered PVP-I. In the placebo control group, the overall positive cultures did not reach 0% until day 14. This result indicates that the PVP-I composition slowed viral replication more effectively than the placebo control.

[0083] Duration of Ad5 shedding. The results of the Ad5 shedding study are shown in FIG. 4. In the treatment group administered the 0.8% PVP-I composition, the median duration of Ad5 shedding was as few days, whereas the placebo control group showed shedding in 11 days. This indicated a statistically significant reduction in viral shedding in the group administered the PVP-I composition (p-value=0.0017). This result indicated that the PVP-I composition reduced the length of infection compared to the placebo control.

[0084] Thus, this study confirmed the in vivo antiviral activity using the Ad5 / NZW rabbit eye model and also confirmed that the composition did not exhibit greater ocular toxicity than the placebo control.

[0085] Example 2 - Stability and Potency The compositions of the present disclosure were prepared according to the methods described herein and had a povidone-iodine concentration of 0.8%. The compositions were provided to a third-party quality testing service on January 20, 2021. The compositions were stored at room temperature during potency testing. The compositions were tested for potency on February 2, 2021 and at 30-day intervals thereafter. Table 1 shows the results of the potency testing. A composition was determined to be potent if the amount of povidone-iodine in the composition was 85.0-120.0% of the label claim. Potency was determined by titration. [Table 1-2]

Claims

1. 1. A method for treating infectious conjunctivitis in a subject in need thereof, the method comprising administering to the infected eye of the subject a therapeutically effective amount of a composition comprising about 0.6-1.25% (w / w) povidone-iodine and an amount of an excipient selected from polyvinylpyrrolidone, glycerin, or a combination thereof, wherein the amount of excipient reduces the ocular toxicity of the composition to a level statistically similar to a placebo control on day 9 of a Draize rabbit eye test, and wherein the composition does not comprise a steroidal or non-steroidal anti-inflammatory drug.

2. 10. The method of claim 1, wherein the povidone-iodine has a concentration of about 0.8% (w / w).

3. The method of claim 1 or 2, wherein the composition comprises polyvinylpyrrolidone.

4. The method of claim 3, wherein the composition comprises about 1-2% (w / w) polyvinylpyrrolidone.

5. 5. The method of claim 4, wherein the composition further comprises a preservative, a surfactant, a pH adjuster, a stabilizer, a emollient, or any combination thereof.

6. The method of any one of claims 1 to 5, wherein the composition comprises glycerin.

7. The method of claim 6, wherein the composition comprises about 1-2% (w / w) glycerin.

8. The method of any one of claims 1 to 7, wherein the composition comprises glycerin and polyvinylpyrrolidone.

9. The method according to any one of claims 1 to 8, wherein the composition comprises about 1-2% (w / w) polyvinylpyrrolidone and about 1-2% (w / w) glycerin.

10. The method of claim 5 , wherein the composition comprises a preservative.

11. 11. The method of claim 5 or claim 10, wherein the preservative is selected from the group consisting of benzalkonium chloride, thimerosal, chlorobutanol, methylparaben, propylparaben, phenylethyl alcohol, EDTA, sorbic acid, polyquaternium 1, and any combination thereof.

12. 12. The method of any one of claims 5, 10, or 11, wherein the preservative has a concentration of about 0.001% to 1.0% by weight in the composition.

13. The method of claim 5 , wherein the composition comprises a surfactant.

14. 14. The method of claim 5 or claim 13, wherein the surfactant is selected from the group consisting of polysorbate 20, polysorbate 60, polysorbate 80, Pluronic® F-68, Pluronic® F-84, Pluronic® F-127, Pluronic® P-103, cyclodextrin, nonoxynol-9, Igepal Co-630, tyloxapol, and any combination thereof.

15. 15. The method of any one of claims 5, 13, or 14, wherein the surfactant has a concentration of about 0.01% to 2% by weight in the composition.

16. 6. The method of claim 5, wherein the emollient comprises polyethylene glycol at a concentration of about 4% (w / w).

17. The method of any one of claims 1 to 16, wherein the composition has a pH of about 4.2 to 4.

5.

18. The method of any one of claims 1 to 17, wherein the composition has a pH of about 4.

3.

19. The method of any one of claims 1 to 18, wherein the composition is a viscous solution.

20. 13. The method of any one of the preceding claims, wherein the composition does not comprise a steroidal anti-inflammatory drug, a non-steroidal anti-inflammatory drug, menthol, a menthol derivative, borneol, camphor or N-acetylcysteine ​​in an amount that improves ocular tolerability of the composition.

21. The method according to any one of claims 1 to 20, wherein the infectious conjunctivitis is bacterial conjunctivitis.

22. The method according to any one of claims 1 to 20, wherein the infectious conjunctivitis is viral conjunctivitis.

23. 23. The method of claim 22, wherein the viral conjunctivitis is caused by an adenovirus, a herpes simplex virus, or an enterovirus.

24. 23. The method of claim 22, wherein the viral conjunctivitis is caused by an adenovirus.

25. The method of any one of claims 22 to 24, wherein the treatment results in a measured reduction in viral replication compared to a placebo control.

26. 25. The method of any one of claims 22 to 24, wherein the treatment results in a decrease in viral titer compared to a placebo control.

27. The method of any one of claims 22 to 24, wherein the treatment results in a reduction in positive cultures compared to a placebo control.

28. 25. The method of any one of claims 22 to 24, wherein the treatment results in a decrease in duration of viral shedding compared to a placebo control.